Stephen J. Schuster

Stephen J. Schuster

Auto-generated profile, based on publicly available information

Stephen J. Schuster

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
SSStephen J. Schuster
Stephen J. Schuster
JSJakub Svoboda
Jakub Svoboda
ECElise A. Chong
Elise A. Chong
SNSunita D. Nasta
Sunita D. Nasta
AMAnthony R. Mato
Anthony R. Mato
CJCarl H. June
Carl H. June
Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited.

1 October 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
SSStephen J Schuster
Stephen J Schuster
CTConstantine S Tam
Constantine S Tam
PBPeter Borchmann
Peter Borchmann
NWNina Worel
Nina Worel
JMJoseph P McGuirk
Joseph P McGuirk
RMRichard T Maziarz
Richard T Maziarz

23 February 2017 in Blood
Verified
Journal Article
Open access
PDF file
ECElise A. Chong
Elise A. Chong
JMJ. Joseph Melenhorst
J. Joseph Melenhorst
SLSimon F. Lacey
Simon F. Lacey
DADavid E. Ambrose
David E. Ambrose
VGVanessa Gonzalez
Vanessa Gonzalez
SSStephen J. Schuster
Stephen J. Schuster

24 January 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GGGuido Ghilardi
Guido Ghilardi
JFJoseph A. Fraietta
Joseph A. Fraietta
JGJames N. Gerson
James N. Gerson
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
JMJennifer J. D. Morrissette
Jennifer J. D. Morrissette
MRMarco Ruella
Marco Ruella

17 February 2022 in Blood
Verified
Journal Article
Closed access
PDF file
ECElise A. Chong
Elise A. Chong
CACécile Alanio
Cécile Alanio
JSJakub Svoboda
Jakub Svoboda
SNSunita D. Nasta
Sunita D. Nasta
DLDaniel J. Landsburg
Daniel J. Landsburg
SSStephen J. Schuster
Stephen J. Schuster
CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion and/or an immunosuppressive tumor microenvironment may contribute to CAR T-cell failure. Pembrolizumab, an anti-PD1 immune checkpoint inhibitor, may reverse T-cell exhaustion after CAR T-cell therapy. We treated 12 patients with B-cell lymphomas who were either refractory to (n = 9) or relapsed after (n = 3) CD19-directed CAR T-cell (4-1BB–costimulated) therapy with pembrolizumab 200 mg IV every 3 weeks. Median time from CAR T-cell infusion to first pembrolizumab dose was 3.3 months (range, 0.4-42.8 months). Pembrolizumab was well tolerated, and the only grade ≥3 adverse events related to pembrolizumab were neutropenia (n = 3; 25%). Best overall response rate after pembrolizumab was 25% (3 of 12 patients; 1 complete response; 2 partial responses). One (8%) patient had stable disease; thus, 4 of 12 (33%) patients had clinical benefit. After pembrolizumab, 4 patients with clinical benefit had an increase in percentage of CAR T cells by mass cytometry by time of flight (CyTOF); 3 of 4 of these patients also had increases in CAR19 transgene levels by quantitative polymerase chain reaction. Deep immune profiling using CyTOF revealed increased CAR T-cell activation and proliferation and less T-cell exhaustion in clinical responders. Together, PD1 blockade with pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in some patients with B-cell lymphomas refractory to or relapsed after CAR T-cell therapy. This trial was registered at www.clinicaltrials.gove as #NCT02650999.

31 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
SGSaar Gill
Saar Gill
VVVanessa Vides
Vanessa Vides
NFNoelle V. Frey
Noelle V. Frey
EHElizabeth O. Hexner
Elizabeth O. Hexner
SMSusan Metzger
Susan Metzger
DPDavid L. Porter
David L. Porter
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19 and the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib prompted us to conduct a prospective single-center phase 2 trial in which we added autologous anti-CD19 humanized binding domain T cells (huCART-19) to ibrutinib in patients with CLL not in CR despite ≥6 months of ibrutinib. The primary endpoints were safety, feasibility, and achievement of a CR within 3 months. Of 20 enrolled patients, 19 received huCART-19. The median follow-up for all infused patients was 41 months (range, 0.25-58 months). Eighteen patients developed cytokine release syndrome (CRS; grade 1-2 in 15 of 18 subjects), and 5 developed neurotoxicity (grade 1-2 in 4 patients, grade 4 in 1 patient). While the 3-month CR rate among International Working Group on CLL (iwCLL)-evaluable patients was 44% (90% confidence interval [CI], 23-67%), at 12 months, 72% of patients tested had no measurable residual disease (MRD). The estimated overall and progression-free survival at 48 months were 84% and 70%, respectively. Of 15 patients with undetectable MRD at 3 or 6 months, 13 remain in ongoing CR at the last follow-up. In patients with CLL not achieving a CR despite ≥6 months of ibrutinib, adding huCART-19 mediated a high rate of deep and durable remissions. ClinicalTrials.gov number, NCT02640209.